Skip to main content
SpringerLink
Log in

Neue Arzneikombination bessert Schweißtest und Lungenfunktion

Cystische Fibrose

  • journal club
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Van Goor F, Hadida S, Grootenhuis PD et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011; 108: 18843–48.

    Article  PubMed  PubMed Central  Google Scholar 

Literatur

  • Boyle M, Bell SC, Konstan MW et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527–38.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Elisabethen Krankenhaus, Ginnheimer Str. 3, 60487, Frankfurt/ M, Deutschland

    Joachim Bargon (Ärztlicher Direktor der Katharina Kasper Kliniken, Chefarzt Med. Klinik)

Authors
  1. Joachim Bargon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joachim Bargon.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bargon, J. Neue Arzneikombination bessert Schweißtest und Lungenfunktion. Pneumo News 6, 20–21 (2014). https://doi.org/10.1007/s15033-014-0018-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-014-0018-2

Search

Navigation